Pulse Biosciences, Inc. logo

Pulse Biosciences, Inc. (6L8)

Market Open
13 Oct, 06:01 AM
XMUN XMUN
€
47. 20
-0.2
-0.4219%
€
- Market Cap
- P/E Ratio
- Div Yield
22 Volume
0 Eps
€ 47.4
Previous Close
Add Transaction
Day Range
47.2 47.2
Year Range
11.1 47.4
Want to track 6L8 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6L8 trading today lower at €47.2, a decrease of -0.4219% from yesterday's close, completing a monthly increase of 4.8889% or €2.2. Over the past 12 months, 6L8 stock gained 300%.
6L8 is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.2133%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

6L8 Chart

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.

Marketbeat | 2 months ago
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Pulse Biosciences Q2 Earnings Call Highlights

Pulse Biosciences Q2 Earnings Call Highlights

Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.

Marketbeat | 2 months ago

Pulse Biosciences, Inc. (6L8) FAQ

What is the stock price today?

The current price is €47.20.

On which exchange is it traded?

Pulse Biosciences, Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is 6L8.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Pulse Biosciences, Inc. ever had a stock split?

No, there has never been a stock split.

Pulse Biosciences, Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Paul Arthur LaViolette CEO
XMUN Exchange
US74587B1017 ISIN
US Country
116 Employees
- Last Dividend
- Last Split
18 May 2016 IPO Date

Overview

Pulse Biosciences, Inc. is a pioneering bioelectric medicine company, previously known as Electroblate, Inc. until its name change in December 2015. Founded in 2014, the company has quickly positioned itself at the forefront of medical technology innovation with its headquarters in Hayward, California. The company's core mission revolves around developing novel therapeutic devices that leverage its unique Nano-Pulse Stimulation (NPS) technology. This technology represents a significant advancement in treating a broad spectrum of medical conditions by delivering nano-second pulses of electrical energy directed at targeted cells. Unlike traditional methods, this approach ensures the non-thermal destruction of cells while preserving adjacent non-cellular tissues, marking a new era in precision medicine.

Products and Services

The cornerstone of Pulse Biosciences’ offering is the CellFX System. This platform embodies the practical application of Nano-Pulse Stimulation technology in clinical settings. Details of the product include:

  • CellFX System: A tunable, software-enabled, console-based platform designed for precision. It harnesses the power of nano-second duration pulses of electrical energy. The system's unique capability to non-thermally clear targeted cells without damaging adjacent non-cellular tissue addresses a vast array of medical conditions. Its versatility and efficacy position it as a revolutionary tool in the field of bioelectric medicine.

Contact Information

Address: 601 Brickell Key Drive
Phone: 510 906 4600